Footnote:
Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments September 20, 2022 erstellt
Description:
This article delves into the innovative strategy deployed by Gilead Sciences, Inc., an American biopharmaceutical company, in providing access to its costly Hepatitis C drugs in low-income countries. Faced with immense pressure from humanitarian organizations and potential threats to its patents, Gilead implemented the Anti-Diversion program, leveraging strategic alliances with Indian pharmaceutical manufacturers. This strategy facilitated the supply of cheaper generic versions of their drugs to a large segment of the global population while preserving Gilead's lucrative markets in the U.S. and E.U. Despite initial criticism, the program has proved to be largely successful, fostering a favourable business environment and expanding patient access to lifesaving drugs